Biblioteca Virtual em Saúde

Pesquisa | Influenza A (H1N1)

  • BIREME | OPAS | OMS logo
 

Histórico de pesquisa  ()

Sua seleção  ()

 0 documento(s) selecionado(s).

Refine sua pesquisa

Collapse All  Ocultar
Expand All  Mostrar
Áreas temáticas
Texto completo (5082)
Idioma
Ano de publicação

Enviar por email

Você tem 0 documento(s) selecionado(s).

Nenhum documento selecionado

 
Resultados  1-12 de 7.173
3.

Influenza A and B in a cohort of outpatient children and adolescent with influenza like-illness during two consecutive influenza seasons

Autor(es): Machado, Clarisse M; de Souza, Ana Carolina Mamana Fernandes; Romano, Camila Malta; dos Santos Freire, Wilton; Costa, Ângela Aparecida; Figueiredo, Walter Manso; Pannuti, Cláudio S; Luna, Expedito J A
Fonte: Braz. j. infect. dis;24(1): 73-80, Feb. 2020. tab, graf
LILACS - Literatura Latino-Americana e do Caribe em Ciências da Saúde ID: 1089322
Resumo: ABSTRACT Introduction Influenza is an important cause of morbimortality worldwide. Although people at the extremes of age have a greater risk of complications, influenza has been more frequently investigated in the elderly than in children, and inpatients than outpatients. Yearly vaccination with trivalent or quadrivalent vaccines is the main strategy to control influenza. Objectives Determine the clinical and molecular characteristics of influenza A and B infections in children and adole (mais)
5.

Influenza A Reinfection in Sequential Human Challenge: Implications for Protective Immunity and "Universal" Vaccine Development.

Autor(es): Memoli, Matthew J; Han, Alison; Walters, Kathie-Anne; Czajkowski, Lindsay; Reed, Susan; Athota, Rani; Angela Rosas, Luz; Cervantes-Medina, Adriana; Park, Jae-Keun; Morens, David M; Kash, John C; Taubenberger, Jeffery K
Fonte: Clin Infect Dis;70(5): 748-753, 2020 Feb 14.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 30953061
Resumo: BACKGROUND: Identification of correlates of protection against human influenza A virus infection is important in development of broadly protective ("universal") influenza vaccines. Certain assumptions underlie current vaccine developmental strategies, including that infection with a particular influenza A virus should offer long-term or lifelong protection against that strain, preventing reinfection. In this study we report observations made when 7 volunteers participated in sequential infl (mais)
6.

Immunogenicity of High Dose Influenza Vaccine for Patients with Inflammatory Bowel Disease on Anti-TNF Monotherapy: A Randomized Clinical Trial.

Autor(es): Caldera, Freddy; Hillman, Luke; Saha, Sumona; Wald, Arnold; Grimes, Ian; Zhang, Youqi; Sharpe, Abigail R; Reichelderfer, Mark; Hayney, Mary S
Fonte: Inflamm Bowel Dis;26(4): 593-602, 2020 Mar 04.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31504526
Resumo: BACKGROUND: Patients with inflammatory bowel disease (IBD) on anti-tumor necrosis factor alpha (TNF) agents may have lower immune response to the influenza vaccine. We aimed to evaluate the immunogenicity of the high dose (HD) vs standard dose (SD) influenza vaccine in patients with IBD on anti-TNF monotherapy. METHODS: We performed a randomized clinical trial at a single academic center evaluating the immunogenicity of the HD vs SD influenza vaccine in patients with IBD on anti-TNF monothe (mais)
7.

Influenza vaccine effectiveness estimates against influenza A(H3N2) and A(H1N1) pdm09 among children during school-based outbreaks in the 2016-2017 season in Beijing, China.

Autor(es): Zhang, Li; van der Hoek, Wim; Krafft, Thomas; Pilot, Eva; Asten, Liselotte van; Lin, Ge; Wu, Shuangsheng; Duan, Wei; Yang, Peng; Wang, Quanyi
Fonte: Hum Vaccin Immunother;16(4): 816-822, 2020 Apr 02.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31596661
Resumo: Background: Since 2007, trivalent inactivated influenza vaccine (TIV) has been provided free-of-charge to primary, middle school and high school students in Beijing. However, there have been few school-based studies on influenza vaccine effectiveness (VE). In this report, we estimated influenza VE against laboratory-confirmed influenza illness among school children in Beijing, China during the 2016-2017 influenza season.Methods: The VE of 2016-2017 TIV against laboratory-confirmed influenza (mais)
8.

Factors associated with adverse outcomes during influenza outbreaks in aged care facilities.

Autor(es): Tennant, Elaine; Fletcher, Stephanie; Kakar, Sheena; Najjar, Zeina; Lord, Heidi; Clark, Penelope; Gupta, Leena
Fonte: Aust N Z J Public Health;44(1): 65-72, 2020 Feb.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31617654
Resumo: OBJECTIVE: To explore factors associated with adverse outcomes during influenza outbreaks in residential aged care facilities. METHODS: A retrospective cohort study of all outbreaks reported to three Sydney metropolitan Public Health Units during 2017. RESULTS: A total of 123 outbreaks affected 1,787 residents and 543 staff. Early notification to a Public Health Unit was associated with shorter outbreak duration (p<0.001; B=0.674). Resident attack rates and resident mortality rates were low (mais)
9.

Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection.

Autor(es): Mandon, Elodie Desuzinges; Pizzorno, Andrés; Traversier, Aurélien; Champagne, Anne; Hamelin, Marie Eve; Lina, Bruno; Boivin, Guy; Dejean, Emmanuel; Rosa-Calatrava, Manuel; Jawhari, Anass
Fonte: Vaccine;38(2): 278-287, 2020 Jan 10.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31630939
Resumo: Influenza A viruses cause major morbidity and represent a severe global health problem. Current influenza vaccines are mainly egg-based products requiring the split of whole viruses using classical detergents such as Triton X-100, which implies certain limitations. Here, we report the use of the novel calixarene-based surfactant CALX133ACE as an alternative to classical detergents for influenza inactivated split vaccine preparation. We confirmed that CALX133ACE-based split HA antigens are f (mais)
10.

Effectiveness of influenza vaccine in children in preventing influenza associated hospitalisation, 2018/19, England.

Autor(es): Pebody, R G; Zhao, H; Whitaker, H J; Ellis, J; Donati, M; Zambon, M; Andrews, N
Fonte: Vaccine;38(2): 158-164, 2020 Jan 10.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31648914
Resumo: 2013/14 saw the start of the introduction of a new live attenuated influenza vaccine (LAIV) programme for children in England. 2018/19 saw co-circulation of both A(H1N1)pdm09 and A(H3N2), when LAIV was offered to all healthy children 2-9 years of age. LAIV effectiveness against influenza hospitalisation is not well described. This paper presents the 2018/19 end-of-season adjusted vaccine effectiveness (aVE) against laboratory confirmed influenza related hospitalisation in children aged (mais)
11.

Protection provided by influenza vaccine against influenza-related hospitalisation in ≥65 year olds: Early experience of introduction of a newly licensed adjuvanted vaccine in England in 2018/19.

Autor(es): Pebody, Richard; Whitaker, Heather; Zhao, Hongxin; Andrews, Nick; Ellis, Joanna; Donati, Matthew; Zambon, Maria
Fonte: Vaccine;38(2): 173-179, 2020 Jan 10.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31653528
Resumo: 2018/19 was the first season of introduction in England of a newly licensed adjuvanted influenza vaccine (aTIV) for adults 65 years or older, who were previously offered standard-dose, non-adjuvanted vaccine, achieving uptake levels >70%, often with poor effectiveness. This paper presents the end-of-season adjusted vaccine effectiveness (aVE) against laboratory confirmed influenza hospitalisation in this population. A frequency-matched test negative case control approach was used to es (mais)
12.

Immunogenicity of the inactivated influenza vaccine in children who have undergone allogeneic haematopoietic stem cell transplant.

Autor(es): Ryan, Anne L; Wadia, Ushma D; Jacoby, Peter; Cheung, Laurence C; Kerr, Fiona; Fraser, Chris; Tapp, Heather; Mechinaud, Francoise; Carolan, Louise A; Laurie, Karen L; Barr, Ian G; Blyth, Christopher C; Gottardo, Nicholas G; Richmond, Peter C; Kotecha, Rishi S
Fonte: Bone Marrow Transplant;55(4): 773-779, 2020 Apr.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31659236
Resumo: Influenza vaccination is recommended for children following allogeneic haematopoietic stem cell transplant (HSCT), however there is limited evidence regarding its benefit. A prospective multicentre study was conducted to evaluate the immunogenicity of the inactivated influenza vaccine in children who have undergone HSCT compared with healthy age-matched controls. Participants were vaccinated between 2013 and 2016 according to Australian guidelines. Influenza-specific hemagglutinin inhibitio (mais)
Resultados  1-12 de 7.173